Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Keeps Sector Perform Rating at Royal Bank Of Canada

Regeneron Pharmaceuticals (NASDAQ:REGN)‘s stock had its “sector perform” rating reaffirmed by research analysts at Royal Bank Of Canada in a note issued to investors on Tuesday, Benzinga reports. They currently have a $737.00 price target on the biopharmaceutical company’s stock. Royal Bank Of Canada’s price target suggests a potential downside of 1.08% from the stock’s current price.

Other analysts also recently issued research reports about the stock. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a report on Monday, September 21st. Sanford C. Bernstein raised shares of Regeneron Pharmaceuticals to a “hold” rating in a report on Wednesday, July 29th. Wall Street Zen raised shares of Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Sunday, September 20th. Leerink Partners boosted their price objective on shares of Regeneron Pharmaceuticals from $641.00 to $824.00 and gave the stock a “market perform” rating in a report on Monday, August 17th. Finally, Benchmark raised shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $185.00 price objective on the stock in a report on Tuesday, July 7th. Fourteen investment analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $802.18.

Regeneron Pharmaceuticals Stock Performance

Shares of NASDAQ:REGN traded down $7.19 during midday trading on Tuesday, hitting $745.07. The stock had a trading volume of 110,895 shares, compared to its average volume of 826,622. The company has a market capitalization of $76.71 billion, a PE ratio of 18.39, a P/E/G ratio of 1.54 and a beta of 0.20. The stock has a 50 day moving average price of $781.41 and a two-hundred day moving average price of $720.99. The company has a current ratio of 3.34, a quick ratio of 2.78 and a debt-to-equity ratio of 0.06. Regeneron Pharmaceuticals has a 1 year low of $541.00 and a 1 year high of $859.34.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share for the quarter, beating the consensus estimate of $10.16 by $4.13. The business had revenue of $4.29 billion for the quarter, compared to the consensus estimate of $3.82 billion. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The business’s quarterly revenue was up 16.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $12.81 earnings per share. As a group, equities analysts predict that Regeneron Pharmaceuticals will post 44.25 earnings per share for the current fiscal year.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Huda Zoghbi sold 800 shares of Regeneron Pharmaceuticals stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $800.00, for a total transaction of $640,000.00. Following the completion of the transaction, the director owned 1,703 shares in the company, valued at approximately $1,362,400. The trade was a 31.96% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Arthur Ryan sold 200 shares of Regeneron Pharmaceuticals stock in a transaction dated Thursday, July 2nd. The stock was sold at an average price of $650.15, for a total transaction of $130,030.00. Following the transaction, the director owned 17,303 shares of the company’s stock, valued at approximately $11,249,545.45. The trade was a 1.14% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 4,146 shares of company stock worth $3,432,488. 6.97% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

A number of institutional investors have recently modified their holdings of REGN. Western Wealth Management LLC acquired a new position in Regeneron Pharmaceuticals during the first quarter worth approximately $26,000. SHP Wealth Management acquired a new position in Regeneron Pharmaceuticals during the fourth quarter worth approximately $26,000. Titan Wealth CI Ltd acquired a new position in Regeneron Pharmaceuticals during the fourth quarter worth approximately $29,000. MCF Advisors LLC increased its position in Regeneron Pharmaceuticals by 50.0% during the fourth quarter. MCF Advisors LLC now owns 45 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 15 shares during the last quarter. Finally, Mowery & Schoenfeld Wealth Management LLC acquired a new position in Regeneron Pharmaceuticals during the second quarter worth approximately $29,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals News Roundup

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Regeneron’s Libtayo cancer treatment is being evaluated in combination with Biohaven’s experimental BHV-1530 in patients with solid tumors, with enrollment in the combination cohort already underway. The agreement could support additional clinical applications and potential long-term growth for Libtayo. Why Did Regeneron Pharmaceuticals Stock Drop Today?
• Neutral Sentiment: Regeneron is expected to report third-quarter results next month, making the upcoming earnings release a potential catalyst. Investors will likely focus on Eylea sales, operating performance and updates on the company’s broader pipeline. Should You Buy Regeneron Pharmaceuticals Stock Before Oct. 30?
• Negative Sentiment: Kodiak Sciences reported Phase 3 data indicating that its investigational eye drugs, Zenkuda and tabirafusp alfa tedromer, matched Eylea on key efficacy endpoints for wet age-related macular degeneration. Their roughly six-month dosing interval, compared with Eylea’s typical eight-week schedule, raises concerns about future competitive pressure and potential pricing or market-share erosion. Kodiak skyrockets on positive study data for two eye drugs
• Negative Sentiment: Royal Bank of Canada reaffirmed its “sector perform” rating and set a $737 price target, below the reference price, signaling limited near-term upside in the analyst’s view. Royal Bank of Canada rating update

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses human genetics, antibody technology and other biological research platforms to develop treatments in areas including eye diseases, cancer, cardiovascular and metabolic disorders, inflammatory diseases, infectious diseases and rare conditions.

Regeneron’s marketed products include EYLEA and EYLEA HD for certain retinal diseases; Dupixent, developed and commercialized with Sanofi, for multiple allergic and inflammatory conditions; Libtayo for certain cancers; Praluent for high cholesterol; Kevzara for rheumatoid arthritis and other inflammatory diseases; Evkeeza for homozygous familial hypercholesterolemia; and Veopoz for a rare immune-mediated disorder.